Firocoxib Market

The Firocoxib market is witnessing a CAGR of 5.2% during the forecast period of 2025-2035. Firocoxib is a selective cyclooxygenase-2 (COX-2) inhibitor of the non-steroidal anti-inflammatory drug (NSAID) class, used mainly in veterinary practice for the treatment of pain and inflammation related to osteoarthritis and postoperative recovery in dogs and horses. Its selective inhibition of COX-2 enzymes enables successful relief of inflammation with reduced gastrointestinal side effects traditionally associated with non-selective NSAIDs

The veterinary drug market has seen significant growth, fueled by a growing pet population and increased awareness of animal health. In 2024, the global market for veterinary medicine was around USD 33.88 billion and is expected to grow to USD 53.47 billion by 2033, with a compound annual growth rate (CAGR) of 5.2% over the forecast period. In this growing market, the need for efficient pain management products such as firocoxib has increased, especially for companion animals with chronic diseases like osteoarthritis.

A number of pharmaceutical firms have seen the possibility of firocoxib and launched formulations to meet this demand. For example, Norbrook Inc. introduced Firox™ (firocoxib) Chewable Tablets, providing veterinarians with a budget-friendly alternative for managing pain and inflammation in dogs. Likewise, PRN Pharmacal Inc. offers firocoxib tablets specifically for equine application to meet the requirements of horse owners and veterinarians.

Regulatory agencies have also contributed to the market dynamics of firocoxib. In September 2024, the European Medicines Agency’s Committee for Veterinary Medicinal Products adopted a favorable opinion for ArthriCox, a firocoxib-containing product by Chanelle Pharmaceuticals Manufacturing Ltd, for pain relief in dogs that are being operated on or have osteoarthritis. Such approvals make it easier to bring new products into the market, increasing treatment options for veterinarians.